Today: 19 March 2026
Subscribe
Browse Category

Biotechnology 13 January 2026 - 22 January 2026

Thermo Fisher stock price today: TMO steadies near a 52-week high ahead of Jan. 29 earnings

Thermo Fisher stock price today: TMO steadies near a 52-week high ahead of Jan. 29 earnings

Thermo Fisher shares rose $2.03 to $638.33 Thursday afternoon, trading near a 52-week high after closing Wednesday at $636.30. Investors are watching for fourth-quarter and full-year results due Jan. 29. The company recently delisted its 3.200% senior notes due 2026 from the NYSE. Thermo Fisher earlier announced a collaboration with Nvidia on AI-based lab automation tools.
22 January 2026
··
Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna shares rose 7.7% to $53.65 Thursday after five-year data showed its personalized cancer vaccine with Merck’s Keytruda cut melanoma recurrence or death risk by 49%. The phase 2b trial enrolled 157 patients and met its primary endpoint. Investors await phase 3 trial updates and Moderna’s Feb. 13 results call. The stock had jumped 15.8% Wednesday on the initial data release.
22 January 2026
··
Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Vertex Pharmaceuticals shares rose 4.31% to $461.14, extending gains for a third session with trading volume above the 50-day average. The company will report fourth-quarter and full-year 2025 results after the U.S. market closes on Feb. 12, followed by a conference call. Director Bruce I. Sachs received 107.088 deferred stock units, according to a Jan. 15 regulatory filing.
22 January 2026
···
Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna shares held steady at $49.81 premarket Thursday after surging 15.8% on five-year melanoma data for its cancer vaccine with Merck. The vaccine-Keytruda combo cut recurrence or death risk by 49% versus Keytruda alone. U.S. vaccine-policy uncertainty is adding risk for the sector. Investors await Moderna’s Feb. 13 earnings call for updates on oncology data and 2026 sales.
22 January 2026
··
Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Corvus Pharmaceuticals shares fell 8% to $19.68 in premarket trading Wednesday after announcing a $150 million stock-and-warrant offering. The drop follows a 167% surge Tuesday on positive Phase 1 data for soquelitinib in atopic dermatitis. Corvus paused its $100 million at-the-market share sales facility ahead of the new deal. No severe adverse events were reported in the trial.
21 January 2026
···
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck shares traded near $108.82 Tuesday after Merck and Moderna reported their personalized melanoma vaccine with Keytruda cut recurrence or death risk by 49% over five years in a phase 2b trial. The stock showed little change following the update. More data will be presented at a future medical meeting. Investors await Merck’s Feb. 3 earnings call for further details on its oncology portfolio.
20 January 2026
····
Qiagen stock price jumps nearly 16% as Bloomberg report revives sale talk

Qiagen stock price jumps nearly 16% as Bloomberg report revives sale talk

Qiagen shares jumped 15.9% to $55.13 in U.S. trading Tuesday after reports the diagnostics firm is exploring strategic options, including a potential sale, and has hired advisers. Bloomberg said the company’s board is handling new takeover interest, but talks remain preliminary. Qiagen will report fourth-quarter results Feb. 4, with a conference call set for Feb. 5. The company has not commented on the reports.
20 January 2026
··
ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update

ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update

ImmunityBio shares surged 39.8% Friday after reporting a 750% jump in 2025 ANKTIVA sales and new regulatory approvals, including in Saudi Arabia. The company said its pivotal bladder cancer trial is over 85% enrolled, with completion targeted for Q2 2026. ImmunityBio ended the quarter with $242.8 million in cash. Investors await audited 2025 results and further updates on ANKTIVA and CAR-NK programs.
17 January 2026
···
Thermo Fisher Scientific stock slips into long weekend as TMO traders eye Jan. 29 earnings

Thermo Fisher Scientific stock slips into long weekend as TMO traders eye Jan. 29 earnings

Thermo Fisher Scientific closed down 0.9% at $618.72 Friday, with little change after hours. A WARN notice filed in North Carolina showed the company will close its Asheville site, affecting 421 workers. Investors are watching for Q4 and full-year results on Jan. 29. The company recently announced a partnership with NVIDIA focused on lab automation and AI.
17 January 2026
···
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie shares fell 1.1% to $214.35 Friday after its lymphoma drug epcoritamab met a key trial goal but failed to show a statistically significant overall survival benefit. The company said it will consult regulators on next steps. AbbVie also outlined plans to expand into obesity drugs and will report earnings Feb. 4. U.S. markets close Monday for Martin Luther King Jr. Day.
16 January 2026
···
ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio shares surged 35% Friday after reporting faster enrollment and positive interim results in its ANKTIVA bladder cancer trial. The company also disclosed $113 million in 2025 preliminary revenue and Saudi approval for ANKTIVA in lung cancer. Shares traded at $5.34 by midday with 133 million shares changing hands. Early data from its CD19 CAR-NK cell therapy showed complete responses in Waldenström lymphoma.
16 January 2026
···
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

ImmunityBio shares jumped 16.5% to $4.60 Friday after the company reported $113 million in preliminary 2025 net product revenue from ANKTIVA and disclosed accelerated approvals in Saudi Arabia for lung and bladder cancer uses. Trading volume topped 56 million shares. Enrollment in the company’s pivotal bladder-cancer trial surpassed 85%, with FDA filing planned by late 2026.
16 January 2026
···
Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Terns Pharmaceuticals shares rose 10.4% to $38.03 by midday Wednesday after the company announced 2026 targets for its chronic myeloid leukemia drug at the JPMorgan Healthcare Conference. The company plans a pivotal dose selection and an FDA meeting by mid-2026, following early trial data showing a 75% major molecular response at 24 weeks. Investors are watching for longer-term results and regulatory milestones.
14 January 2026
··
KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next

KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next

Kiniksa shares fell 6.1% to $38.61 Tuesday after the company projected 2026 ARCALYST revenue of $900–$920 million, below the prior year’s growth rate. The drop followed an intraday low of $38.27. Wedbush raised its price target to $50, citing increased prescriber numbers and longer therapy use. Kiniksa reported $677.5 million in 2025 ARCALYST revenue and ended the year with $414.1 million in cash.
13 January 2026
····
1 2 3 4 5 … 16

Stock Market Today

  • Forum Energy Technologies Sees 46% Backlog Rise, Boosting Long-Term Growth Prospects
    March 19, 2026, 3:20 PM EDT. Forum Energy Technologies (FET) enters 2026 with a 46% increase in backlog to $312 million, marking its highest year-end backlog in 11 years. The firm, a key supplier to oil, gas, and renewables sectors, reported a book-to-bill ratio of 113%, indicating orders outpaced shipments. This growth stems from its 'Beat the Market' strategy, focusing on product differentiation and expanding market reach. Despite subdued North American drilling, FET's diverse global presence and innovation pipeline provide revenue visibility and long-term growth potential. Peer companies NESR and NOV, active in oilfield services and equipment, show varied market momentum, with NESR rising 156.5% in a year and NOV maintaining steady revenue growth driven by higher-quality production projects.
Go toTop